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Erythropoietin—hematocrit feedback circuit in the anemia of end—stage
renal disease. Deficient erythropoietin (EP) production is thought to be
a key factor in the pathogenesis of the anemia of end—stage renal
disease. We describe the interrelationships between radioimmunoas-
sayed plasma EP levels, reticulocyte counts corrected for anemia
(CRC) and hematocrit (HCT) under challenge by hemorrhage, transfu-
sions and hemodialysis in 32 chronically—hemodialyzed patients. Spon-
taneous hemorrhage resulted in a decrease in HCT (P = 0.001) and
increases in both EP (P = 0.006) and CRC levels (P = 0.0065).
Transfusions of two units of packed red cells into each of 16 patients
suppressed EP (P 0.0004) and CRC (P < 0.0001) after about 28 and
42 hours, respectively. Repeat transfusions after one to 27 days resulted
in similarly significant suppressions of both EP and CRC, except the
CRC remained on higher levels for prolonged periods of times. Within
a few hours after each transfusion of 2,3-diphosphoglycerate—poor red
cells, both EP (P = 0.009) and CRC (P = 0.007) increased temporarily
between one to 18 and three to 38 hours, respectively. Hemodialysis
resulted in alkalinization (P = 0.008) of blood but not in changes of EP
or CRC counts. The data show that, with the EP—HCT feedback loop
persisting, increased endogenous hormone levels elicit erythropoietic
responses, and that the regulation of EP levels may involve determi-
nants such as oxy-deoxyhemoglobin interactions.
In healthy subjects plasma erythropoietin (EP) exerts a
continuous stimulus on the bone marrow to help maintain the
level of oxygen carriers in the blood required to satisfy the
oxygen needs of the body. It has been shown that acute
hemorrhage increases plasma levels of EP [1, 2]. EP levels are
suppressed after transfusions [1]. Assuming a constant catabo-
lism of the hormone in vivo, studies of the erythropoietin—
hematocrit feedback ioop may provide evidence of balance or
acute imbalance between oxygen needs of and oxygen supply to
tissues. Lack of EP production capacity has been considered a
key factor [2—6] in the pathogenesis of the anemia of end—stage
renal disease (ESRD), while uremic toxins of some sort pre-
sumably inhibit erythropoiesis [7—10]. Studies on erythron iron
turnover in uremic patients lead to the speculation that hyper-
transfusion—induced suppression of erythropoiesis might be
mediated by a depression in EP production [11]. The present
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study shows that the principal patterns of responses of cor-
rected reticulocyte count (CRC) and EP to alterations in hem-
atocrit (HCT) are similar in patients with ESRD and normal
subjects. This suggests that a functioning EP—HCT feedback
mechanism operates on a low level of HCT in chronic uremic
patients.
Methods
Patients
Thirty—two consecutive patients (26 males, 6 females; mean
age 31 years, non-smokers) who had been on chronic intermit-
tent hemodialysis for end—stage renal disease (ESRD) for 13 (2
to 59) months, gave informed consent to participate in this
study. Acetate dialysis was performed three times a week for
four hours on each patient in a center—based dialysis program.
Carbon monoxide and methemoglobin concentrations in blood
were within normal limits in all patients. Clinical diagnoses
were chronic glomerulonephritis and pyelonephritis (N = 24),
diabetic nephropathy (N = 5), postradiation nephritis and drug—
related interstitial nephritis (N = 3). Except patient #3 who was
bilaterally nephrectomized for control of hypertension 18
months prior to the study, all patients had their kidneys in situ.
All patients were in clinically stable condition without acute
distress. About one—third of the patients were able to carry out
normal physiological activity part of the time, and about
one—half of them were able to carry out only physical activity
involving self—care. The rest of the patients required at least
some assistance for care of bodily needs. None of the patients
received anti-anemic treatments such as vitamins, folic acid,
ferrous salt and androgens for at least two months prior to the
study.
Laboratory methods
Heparinized blood samples were drawn from the arterial
branch of the antebrachial dialysis fistula. HCT values were
determined by microhematocrit centrifugation. Two different
smears of each blood sample were stained with methylene blue
and evaluated for reticulocytes (criteria of different degrees of
maturity [121) by two technicians on two different occasions;
that is, each blood sample was scanned eight times for the
number of reticulocytes in 1,000 erythrocytes. The mean retic-
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Table 1. Hematologic data of 16 dialysis patients before first and second transfusions
Patients 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Mean 1 so
First transfusion experiment
HCT % 18.0 21.0 16.0 16.0 11.2 14.9 13.8 18.2 16.7 19.6 20.5 15.2 19.1 15.0 16.1 18.7 16.9 2.6
CRC% 14 13 18 16 21 45 8 7 4 16 5 7 11 20 9 27 15.1 10.2
EP mU/mi 16.7 13.6 594.6 74.4 25.7 25.0 30.1 27.7 10.2 8.9 9.5 14.8 48.1 25.9 14.5 29.6 25.0 17•2b
Time day? 39 27 51 12 14 23 27 49 80 51 38 38 65 17 40 12 —
Second transfusion experiment
HCT% 28.7 28.0 23.4 25.0 20.2 21.9 17.0 29.7 26.0 29.4 13.2 21.5 29.3 32.5 26.0 — 24.8±5.1
CRC % 13 4 15 14 18 39 5 9 2 8 8 13 16 10 33 — 13.8 10.0
EP mU/mi 10.0 10.5 — 28.7 8.4 — 13.4 10.9 7.5 7.3 — — 72.4 10.3 9.1 16.8 16.4 17.1
Time day? 2 4 1 1 2 2 12 12 3 2 27 20 22 2 4 7 —
a Time, indicates the number of days of last transfusion given prior to the present one.
' Mean value excludes outlier #3.
Time, indicates the number of days between administration of the first and second transfusions.
ulocyte count of these eight determinations was corrected for
the degree of anemia by multiplication with the actual hemato-
crit divided by 45. Whole blood pH was measured anaerobically
from a 50 pi sample of blood at 37°C using the CombiAnalysator
MT 1-2-31 (Eschweiler & Co., Kid, FRG) [131. The technique
of the radioimmunoassay of EP has been published [14]. The
2,3-diphosphoglycerate (2,3-DPG) content of ACD-stored red
cells was determined by the enzymatic UV-Test kit (Boehringer
Ingelheim, FRG), and amounted to 2.1 0.9 tM/ml erythro-
cytes. Fresh control erythrocytes of 21 healthy non-smoking
donors had 4.37 0.51 M 2,3-DPG/ml erythrocytes.
Statistical evaluation
Both paired t-tests and two—sample t-tests with either one— or
two—sided alternatives were used to establish statistical signif-
icance of pre-transfusion and post-transfusion results. Normal
probability plots were employed to assess the validity of the
normality assumption used in the significance testing. Given the
present sample size, none of the plots suggested that a normal-
izing transformation was warranted. Standard adjustments to
the heterogeneity of variances in two-sample t-tests were made
whenever necessary. The significance of the magnitude of a
correlation coefficient was tested using simple linear regression
method.
Experimental designs
Three types of clinical situations were studied. A first trans-
fusion experiment included 16 patients who had not received
any transfusions for an average of 36.4 (12 to 80) days prior to
the study (Table I). Blood samples were drawn before, early
and late after transfusions of two units of 200 ml of packed red
cells. The exact times are indicated in Figures 1 and 2. A second
transfusion experiment scheduled in a similar manner included
the same patients. The second transfusions were administered
an average of 7.7 (1 to 27) days after start of administration of
the first transfusions (Table 1). Three of these patients took part
in a study to determine in detail the profile of EP levels after a
transfusion regimen.
The second clinical situation consisted of eight patients with
spontaneous hemorrhage (N = 4: erosive gastritis; N = 3: anal
bleeding from hemorrhoids; N= 1: vaginal bleeding) who were
studied over a period of time of 9.7 (2 to 34) days (Table 2).
The final clinical situation was comprised of eight patients on
regular hemodialysis who had an uneventful clinical course.
These patients were studied before and at termination of
dialysis (Table 3).
Results
The studies were performed at 10 to 25 meters above sea
level. The average HCT, CRC and EP values of 16 patients
before administration of transfusions are recorded in Table 1.
The sample correlation coefficients (r) between the pairs of
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Fig. 1. Post-transfusional deviations in percent of pretransfusional
baseline values (Table 1) of plasma EP levels (A), CRC (B) and HCT (C)
during the first transfusion experiment. Hatched bars indicate areas of
estimated transitions from above to below baseline values, or vice
versa. B. Negative values of CRC during the first two hours after
transfusions are likely due to dilution of circulating retriculocytes by
transfused blood. Mean % of EP between I and 18 hours differs from
the one between 28 and 96 hours at P < 0.0001. Mean % of CRC
between 3 and 38 hours differs from the one between 42 and 96 hours at
P < 0.0001.
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Fig. 2. Post-transfusional deviations in percent of pre-transfusional
baseline values (Table 1) of plasma EP levels (A), CRC (B) and HCT (C)
during the second transfusion experiment. Hatched bars indicate areas
of estimated transitions from above to below baseline values, or vice
versa. Mean % of EP between 3 and 9 hours differs from the one
between 24 and 168 hours at P < 0.0001. Mean % of CRC between 3 and
72 hours differs from the one between 96 and 168 hours at P = 0.0009.
HCT and CRC, HCT and EP, and EP and CRC are —0.26,
—0.20 and 0.17, respectively (all nonsignificant). Administra-
tion of 400 ml of packed red cells raised the HCT to 24.8% (P <
0.0001), whereas the mean CRC dropped to 11.9 %o(P < 0.0001)
42 to 96 hours after transfusions, and plasma EP fell to 12.5
mU/mi (P = 0.0004, disregarding the outlier #3) 28 to 96 hours
after transfusions. The r values of the pre- versus late post-
transfusional values of HCT, CRC and EP levels were 0.55,
0.86 and 0.88, respectively. Figure 1 demonstrates the time
dependent fluctuations of the changes of EP levels and CRC.
The mean increase in plasma EP concentrations between one
and 18 hours post-transfusion was significantly different from
pre-transfusion levels (P = 0.0085, omitting the outlier #3). The
maximum early increases and late decreases in hormone levels
were observed about three and 48 hours after transfusions,
respectively. The mean increase over baseline levels of CRC
between three and 48 hours after transfusions was significant (P
= 0.0065). The maximum early increases and subsequent late
decreases in CRC were observed about 12 and 60 hours after
transfusions, respectively.
In order to test the sensitivity of the regulatory mechanisms
between HCT and EP, and the reproducibility of this relation-
ship on higher levels of HCT, the same study was carried out in
the same patients an average of 9.7 (3 to 30) days after start of
the first transfusion study. The mean HCT, CRC and EP levels
before the second transfusion study were essentially unchanged
from the previous post-transfusional values (Table 1). In keep-
ing with the first transfusion experiment, the early post-trans-
fusion period (2 to 9 hours) was characterized by increases in
mean HCT (P < 0.0001), EP (P = 0.0005, omitting the outlier
#13) and CRC (3 to 72 hours, P = 0.0040). During the later
post-transfusional period of 22 to 168 hours, EP dropped below
baseline levels (P = 0.045, omitting #13), but CRC remained
elevated for a prolonged period of time and declined below
baseline levels only after more than 76 hours (Fig. 2). The
reticulocytes appearing in the circulation after the second
transfusion were more immature than those after the first
transfusion. Frequent blood sampling during the steep rises and
declines of plasma EP concentrations after transfusions in three
patients demonstrated that hormone levels may rise at rates of
39 55 mU/ml/hr (one episode in each of 3 patients: 5, 10 and
102 mU/ml/hr, respectively) and decline at rates of 25 23
mU/mi/hr (one episode in each of 2 patients and three episodes
in one patient: 2, 5, 21,49 and 50 mU/ml/hr, respectively). Since
it is unknown whether the production of EP had ceased
completely, the rates of declines cannot serve as estimates of
the intravascular half—life time of the hormone.
Eight patients with acute spontaneous hemorrhage were
studied for an average period of time of 9.7 (2 to 34) days
following diagnosis of hemorrhage (Table 2). During these
episodes the mean HCT declined (P = 0.0005), and EP and
CRC increased (P = 0.006 and 0.0065, respectively).
To probe the effect of hemodialysis on plasma EP concentra-
tions, the hormone was measured immediately prior to, or at
the very beginning of hemodialysis, and at termination of the
procedure (Table 3). Independent of the baseline levels of the
hormone before start of dialysis, no significant changes in EP
levels occurred during four hours of dialysis. The r value of pre-
versus postdialysis EP levels was 0.89. Yet, the HCT rose as a
result of the removal of water. During the same period of time,
the blood pH rose (P = 0.0083, Table 3).
Discussion
Significant fluctuations in endogenous plasma EP levels in
patients with ESRD were induced by transfusions of packed red
cells and by hemorrhage, but not by regular hemodialysis.
When transfusions were given, the hormone levels were sup-
pressed after 24 hours and remained so for the rest of the
observation period of up to 168 hours (Figs. 1, 2). The decrease
in plasma EP levels was accompanied by a significant reduction
in levels of CRC (Fig. 1) beginning about 24 hours post-
transfusion. Transfusions of blood into anephric patients had
previously been shown to decrease both normoblast counts in
the bone marrow [151 and erythron iron turnover [11]. Simi-
larly, the second transfusion experiment (Fig. 2) shows that
even on the elevated mean level of HCT of 24.8% the EP—HCT
axis can be triggered to react to another increment in HCT with
a significant suppression of EP and CRC levels after about 24
and 96 hours, respectively (Fig. 2). In conclusion, these trans-
fusion experiments as well as the observations during episodes
of acute and prolonged spontaneous hemorrhage (Table 2)
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Table 2. Hematologic data of eight dialysis patients experiencing minor to moderate spontaneous hemorrhages of variable duration
Hematocrit (%)
Corrected reticul
count %
ocyte Plasma Erythrop
mU/mi
oietin Observed
period of
bleeding
days
.Patients From To From ToFrom To
1 25.8 16,8 0.4 10.8 9.0 14.7 7
2 19.4 13.4 4.7 9.2 10.5 30.0 7
3 21.4 13.2 4.8 8.8 13.3 19.5 7
4 40.2 27.5 11.6 12.2 7.7 14.2 12
5 25.8 16.1 1.1 10.2 8.0 9.7 7
6 30.7 27.8 17.1 36.4 6.2 11.0 2
7 36.6 27.6 0.2 6.1 8.0 11.0 34
8 35.3
P = 0.0005
33.2 3.1
P = 0.0065
5.2 10.5
P = 0.006
15.5 2
Mean 29.40 22.04 5.38 12.44 9.15 15.70 9.7
si 7.03 7.30 5.61 9.32 2.07 6.15 9.6
P values indicate probability levels for a one—sided paired t-test.
Table 3. Hematologic data of eight patients before and at termination
of one dialysis session of four hours duration
Patients
N=8
Hematocrit
%
Corrected
reticulocyte
count%o
Plasma
erythropoietin
mU/mi
Whole blood
pH
Before 24.5 5.1 12.5 4.8 26.1 19.2 7.36 0.02
After 27.9 5.3
P = 0.024
13.8 6.6
NS
28.3 23.4
NS
7.40
P = 0.0083
P values indicate probability levels for a two—tailed paired t-test.
suggest that a negative feedback mechanism exists between
HCT and EP. Furthermore, increases in radioimmunoassayed
EP activity, as well as bioassayed hormone [16], are associated
with both release of reticulocytes from the bone marrow and
stimulation of erythropoiesis as reflected by appearance of
immature reticulocytes in the circulation with prolonged eleva-
tion of CRC. In non-renal anemias excellent reproducibility and
correlation of radioimmunoassayed with bioassayed erythropoi-
etin levels have been reported [17, 181. The significant rise in
both EP and CRC levels during the early post-transfusional
periods (Figs. 1, 2) may be related to transfusion of 2,3-DPG
poor red cells [19—21] with their known increased oxygen
affinity of hemoglobin [22—24]. After less than 24 hours post-
transfusion, both the partial restoration in vivo of the 2,3-DPG
pools of the transfused red cells [19, 20] and the EP-induced
influx into the blood of young red cells known for their
high—oxygen release capacity [24—26] succeeded in reversing
this transient state of decreased oxygen delivery capacity. The
decreases in HCT with associated increases in EP and CRC in
patients with spontaneous hemorrhage also indicate a func-
tional relationship between the HCT and erythropoiesis proba-
bly mediated by EP (Table 2).
The observation of steady levels of EP during hemodialysis
suggests that the alkaline Bohr effect on the oxy-deoxyhemo-
globin dissociation curve did not lead to an acute oxygen
deficiency situation, although dialysis—associated decreases in
p50 of oxyhemoglobin in vivo have been described [27, 28].
Appropriately, the CRC remained steady during dialysis in our
study (Table 3) and a previous study [29]. Hence, other
dialysis—associated changes such as oxy-deoxyhemoglobin in-
teraction, or hemodynamic parameters [27] are expected to
compensate in part for the left—shift of p50. The finding in this
study of a persistant erythropoietin—reticulocyte—hematocrit
regulation circuit, and of increases in endogenous EP plasma
levels which are associated with increases in reticulocyte
counts raises the option that the previously—advocated
parenteral administration of recombinant EP [3, 4] may be a
valuable regimen for intermittent treatment of patients with
chronic renal anemia.
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